Table 2.
Biomarker | Unadjusted Analysis | Adjusted Analysisa | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
100% Adherence | Suboptimal Adherence | Fold Higher Level Compared With 100% Adherenceb | 95% CI | P Value | Fold Higher Level Compared With 100% Adherenceb | 95% CI | P Value | |||
No. | Mean (SD) | No. | Mean (SD) | |||||||
IL-6, pg/mL | 2372 | 2.60 (6.93) | 391 | 2.93 (4.53) | 1.16 | 1.06–1.26 | .0005 | 1.09 | 1.01–1.18 | .02 |
D-dimer, μg/mL | 2382 | 0.30 (0.59) | 394 | 0.38 (1.06) | 1.17 | 1.05–1.29 | .002 | 1.11 | 1.01–1.22 | .03 |
hsCRP, μg/mL | 2397 | 3.72 (7.08) | 396 | 4.27 (7.51) | 1.07 | 0.94–1.23 | .31 | 1.04 | 0.91–1.17 | .58 |
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; PLWH, people living with HIV.
Models were adjusted for covariates including age, race, gender, body mass index, time on ART, HIV exposure group, baseline viral load, baseline and nadir CD4+ T-cells, hepatitis B or C co-infection, smoking, and regimen type.
100% adherence defined as no report of any missed doses for any drug in the preceding 7-day period.